報價延遲最少15分鐘:2025/07/09 04:50 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.253 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.30/-0.08
|
|
企業價值
133.40M
|
| 資產負債 |
|
每股賬面淨值
-0.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
178.03M
|
|
每股收益
0.27
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/09 04:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |